Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Romidepsin, and Lenalidomide in Relapsed/Refractory Lymphomas
NCT02341014Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2015
- Primary completion
- Jan 2023
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, romidepsin, lenalidomide in B cell lymphoma, T-cell lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2015; status: completed.
02
Drugs
carfilzomibromidepsinlenalidomide
03
Conditions
B cell lymphomaT-cell lymphoma
Beyond the preview
Go deeper on NCT02341014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341014.